About EyePoint, Inc.
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases.
2BBBullish & Bearish
EyePoint, Inc. (EYPT) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 13 out of 100.
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases.
EyePoint, Inc.’s current 2BB score is 13 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 5 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 0 | Very Weak |
| Company Presence | 48 | Normal |
| Risk | 46 | Moderate (provisional) |
| Headquarters | Watertown, Massachusetts, United States |
| Founded | 2000 |
| Employees | 214 |
| 52-week range | $2.93 – $19.01 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-05-04 | — | -0.6018 | — | $130,815.00 |
| 2027-03-02 | — | -0.7157 | — | $299,094.00 |
| 2026-11-12 | — | -0.9492 | — | $227,541.00 |
| 2026-08-05 | — | -0.9705 | — | $414,997.00 |